Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 1.00 |
| ▸ | FBP1 | P09467 | 4/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7093959 | 0.96 | EGFR (0.93) | EGFRFBP1 | |
| SCHEMBL7092904 | 0.96 | EGFR (0.93) | EGFRFBP1 | |
| SCHEMBL7089281 | 0.96 | EGFR (0.93) | EGFRFBP1 | |
| SCHEMBL7094820 | 0.94 | EGFR (0.88) | EGFRFBP1ERBB2ERBB4 | |
| Hydrochloric Acid SCHEMBL7091983 | 0.93 | EGFR (0.86) | EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL7093305 | 0.90 | EGFR (1.00) | EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL7093770 | 0.90 | EGFR (0.82) | EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL7092006 | 0.90 | EGFR (0.82) | EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL7092436 | 0.90 | EGFR (0.81) | EGFRFBP1ERBB2 | |
| SCHEMBL4315736 | 0.89 | EGFR (0.79) | EGFRFBP1ERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187194-A1 | Preventive agents for diabetes mellitus | SANKYO COMPANY LIMITED (JP) | 2005-08-25 | — | — | US | claimed |
| EP-1535630-A1 | PREVENTIVE FOR THE ONSET OF DIABETES | Sankyo Company, Limited (JP) | 2005-06-01 | — | — | EP | claimed |
| US-20030144308-A1 | Fructose 1,6-bisphosphatase inhibitors | BAUER PAUL H (US) | 2003-07-31 | — | — | US | claimed |
| US-20050187194-A1 | Preventive agents for diabetes mellitus | SANKYO COMPANY LIMITED (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1535630-A1 | PREVENTIVE FOR THE ONSET OF DIABETES | Sankyo Company, Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187194-A1 | Preventive agents for diabetes mellitus | FBP1, ALDOA, G6PC1 | EGFR 4127/4885FBP1 1/4885ERBB2 4667/4885 |
| US-20030144308-A1 | Fructose 1,6-bisphosphatase inhibitors | FBP1, HK1, G6PC1 | EGFR 2906/4885FBP1 1/4885ERBB2 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.